A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)

Clinuvel

Status and phase

Completed

Phase 3

Conditions

Erythropoietic Protoporphyria

Treatments

Drug: Afamelanotide

Study type

Interventional

Funder types

Industry

Identifiers

NCT04578496

CUV037

Details and patient eligibility

About

The main objectives of the study were to evaluate the safety and tolerability of afamelanotide by measuring treatment emergent adverse events (AEs) and to determine whether afamelanotide can improve the quality of life of EPP patients.

Enrollment

16 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

male or female subjects with a positive diagnosis of EPP who successfully completed the CUV017 or CUV029 studies;
aged 18-75 years (inclusive);
provide written informed patient consent prior to the performance of any study-specific procedure.

Exclusion criteria

any serious adverse event considered to be related to afamelanotide or the polymer contained in the implant;
any allergy to lignocaine or other local anaesthetic to be used during the administration of the study medication;
EPP patients with significant hepatic involvement;
personal history of melanoma or dysplastic nevus syndrome;
current Bowen's disease, basal cell carcinoma, squamous cell carcinoma, or other malignant or premalignant skin lesions;
any evidence of clinically significant organ dysfunction or any clinically significant deviation from normal in the clinical or laboratory determinations;
acute history of drug or alcohol abuse (in the last 12 months);
female who is pregnant (confirmed by positive serum β-Human Chorionic Gonadotropin (HCG) pregnancy test prior to baseline) or lactating;
females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device);
sexually active men with partners of child-bearing potential not using barrier contraception during the trial and for a period of three months thereafter;
participation in a clinical trial for an investigational agent within 30 days prior to the screening visit;
prior and concomitant therapy with medications which may interfere with the objectives of the study.